Company / Operating Cash Flow
Cogent Biosciences, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$264.4M
FY2025
5-year range
-$264.4M / -$58.8M
FY2021-FY2025
Trend
-27.3%
vs FY2024
Sector context
#184 of 216
Health Care
What the data says
Cogent Biosciences, Inc.'s operating cash flow of -$264M is lower than 85% of companies in the Health Care sector (FY2025). Operating Cash Flow has declined for 5 consecutive years, from -$36M in FY2020 to -$264M in FY2025.
Based on SEC 10-K filings.
-$264M in FY2025.
Declined from -$154M to -$264M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 216This company -$264.4M Sector average $658.7M
▼
-140.1% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 27.3% year-over-year.
- Ranks #184 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$264.4M | -27.3% |
| FY2024 | -$207.8M | -35.3% |
| FY2023 | -$153.6M | -29.5% |
| FY2022 | -$118.6M | -101.9% |
| FY2021 | -$58.8M | -63.9% |
| FY2020 | -$35.9M | +13.6% |
| FY2019 | -$41.5M | -27.8% |
| FY2018 | -$32.5M | -25.8% |
| FY2017 | -$25.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026